JP2017538669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538669A5 JP2017538669A5 JP2017520986A JP2017520986A JP2017538669A5 JP 2017538669 A5 JP2017538669 A5 JP 2017538669A5 JP 2017520986 A JP2017520986 A JP 2017520986A JP 2017520986 A JP2017520986 A JP 2017520986A JP 2017538669 A5 JP2017538669 A5 JP 2017538669A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- group
- mdsc
- human genetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 230000002068 genetic effect Effects 0.000 claims 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 5
- 239000003550 marker Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 101150036449 SIRPA gene Proteins 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940126533 immune checkpoint blocker Drugs 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000034706 Graft dysfunction Diseases 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 1
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- -1 radiation therapy Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021102148A JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14190370.8 | 2014-10-24 | ||
| EP14190370.8A EP3012271A1 (en) | 2014-10-24 | 2014-10-24 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| PCT/IB2015/058124 WO2016063233A1 (en) | 2014-10-24 | 2015-10-21 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102148A Division JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538669A JP2017538669A (ja) | 2017-12-28 |
| JP2017538669A5 true JP2017538669A5 (enExample) | 2018-11-29 |
| JP6918279B2 JP6918279B2 (ja) | 2021-08-11 |
Family
ID=51868772
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520986A Active JP6918279B2 (ja) | 2014-10-24 | 2015-10-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2021102148A Active JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A Pending JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102148A Active JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A Pending JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170247464A1 (enExample) |
| EP (3) | EP3012271A1 (enExample) |
| JP (3) | JP6918279B2 (enExample) |
| CA (1) | CA2964203C (enExample) |
| DK (1) | DK3209691T3 (enExample) |
| ES (1) | ES2817074T3 (enExample) |
| HU (1) | HUE050318T2 (enExample) |
| PL (1) | PL3209691T3 (enExample) |
| WO (1) | WO2016063233A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| SG10202101909RA (en) | 2015-08-07 | 2021-04-29 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| PT3341015T (pt) | 2015-08-26 | 2021-10-12 | Univ Leland Stanford Junior | Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária |
| EP3365370A1 (en) * | 2015-10-21 | 2018-08-29 | OSE Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| EP4438626A3 (en) | 2016-04-14 | 2024-12-04 | OSE Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EP3482772A4 (en) * | 2016-07-05 | 2020-03-04 | National University Corporation Kobe University | Antitumor agent |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| KR20240039236A (ko) | 2016-12-09 | 2024-03-26 | 알렉터 엘엘씨 | 항-sirp-알파 항체 및 그의 사용 방법 |
| PL3565828T3 (pl) | 2017-01-05 | 2022-04-04 | Kahr Medical Ltd. | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| US20190336516A1 (en) * | 2017-01-18 | 2019-11-07 | Nant Holdingsp Ip, Llc | Modulation of tumor cell susceptibility |
| JP7374769B2 (ja) * | 2017-02-15 | 2023-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｎｋ細胞を活性化するための組成物及び方法 |
| US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
| CA3091468A1 (en) | 2018-03-13 | 2019-09-19 | Ose Immunotherapeutics | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
| MA52091A (fr) * | 2018-03-21 | 2021-01-27 | Alx Oncology Inc | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation |
| KR20210015872A (ko) | 2018-05-25 | 2021-02-10 | 알렉터 엘엘씨 | 항-sirpa 항체 및 그의 사용 방법 |
| JP7490554B2 (ja) | 2018-06-14 | 2024-05-27 | 株式会社明治 | 免疫チェックポイント阻害療法を促進するための組成物 |
| CN112543773B (zh) | 2018-07-11 | 2024-05-31 | 卡尔医学有限公司 | SIRPα-4-1BBL变体融合蛋白及其使用方法 |
| KR20210044221A (ko) | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법 |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR102904057B1 (ko) * | 2018-10-19 | 2025-12-24 | 오하이오 스테이트 이노베이션 파운데이션 | 나노-조작된 치료적 스텔스 세포 |
| BR112021024003A2 (pt) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
| CN114206912B (zh) | 2019-06-07 | 2025-02-11 | Alx肿瘤生物技术公司 | 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂 |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| EP4157315A1 (en) | 2020-06-01 | 2023-04-05 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| CN111808800B (zh) * | 2020-07-20 | 2022-08-26 | 中南大学湘雅二医院 | 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| US12098214B2 (en) | 2021-05-13 | 2024-09-24 | ALX Oncology Inc. | Combination therapies for treating cancer |
| WO2023020459A1 (zh) | 2021-08-17 | 2023-02-23 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
| WO2023235754A1 (en) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| CN115896015B (zh) * | 2023-02-08 | 2023-09-29 | 上海诚益生物科技有限公司 | 一种髓系来源抑制性细胞的体外培养方法 |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1048299A1 (en) | 1999-04-28 | 2000-11-02 | Faculteit der Geneeskunde van de Vrije Universiteit | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| JP2011500569A (ja) * | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| ES2740823T5 (en) * | 2008-01-15 | 2025-12-26 | Univ Leland Stanford Junior | Methods for manipulating phagocytosis mediated by cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| JP6091891B2 (ja) | 2009-05-15 | 2017-03-08 | ユニバーシティ・ヘルス・ネットワーク | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| GB201015765D0 (en) * | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| EP3682896A1 (en) * | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013056352A1 (en) * | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| JP6460796B2 (ja) | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性ｓｉｒｐ−アルファ試薬 |
| EA036963B1 (ru) * | 2013-02-06 | 2021-01-20 | Инхибркс, Инк. | Применение эпитопа cd47 для получения антитела к cd47 |
| SG11201607143UA (en) | 2014-03-11 | 2016-09-29 | Univ Leland Stanford Junior | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
-
2014
- 2014-10-24 EP EP14190370.8A patent/EP3012271A1/en not_active Withdrawn
-
2015
- 2015-10-21 EP EP15794641.9A patent/EP3209691B1/en not_active Revoked
- 2015-10-21 WO PCT/IB2015/058124 patent/WO2016063233A1/en not_active Ceased
- 2015-10-21 CA CA2964203A patent/CA2964203C/en active Active
- 2015-10-21 US US15/518,803 patent/US20170247464A1/en not_active Abandoned
- 2015-10-21 JP JP2017520986A patent/JP6918279B2/ja active Active
- 2015-10-21 ES ES15794641T patent/ES2817074T3/es active Active
- 2015-10-21 HU HUE15794641A patent/HUE050318T2/hu unknown
- 2015-10-21 DK DK15794641.9T patent/DK3209691T3/da active
- 2015-10-21 PL PL15794641T patent/PL3209691T3/pl unknown
- 2015-10-21 EP EP20177260.5A patent/EP3783027B1/en active Active
-
2021
- 2021-06-21 JP JP2021102148A patent/JP7253008B2/ja active Active
-
2022
- 2022-05-20 US US17/749,856 patent/US20220281993A1/en not_active Abandoned
-
2023
- 2023-03-24 JP JP2023047480A patent/JP2023078398A/ja active Pending
-
2024
- 2024-04-25 US US18/645,607 patent/US20240294659A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538669A5 (enExample) | ||
| Chen et al. | Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response | |
| Gottstein et al. | Susceptibility versus resistance in alveolar echinococcosis (larval infection with Echinococcus multilocularis) | |
| Khammari et al. | Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones | |
| MX2019005125A (es) | Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. | |
| Pircher et al. | Neoadjuvant chemo-immunotherapy modifies CD4+ CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients | |
| JP2009525478A5 (enExample) | ||
| Conti et al. | Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB‐neuT Mice | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| JP2013539857A5 (enExample) | ||
| MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| JP2016501013A5 (enExample) | ||
| EA201591219A1 (ru) | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение | |
| WO2019079624A3 (en) | Msi from liquid biopsies | |
| WO2007071389A1 (en) | Method for treating disseminated cancer | |
| Costa et al. | Diagnosis of human strongyloidiasis: Application in clinical practice | |
| MX2017013177A (es) | Anticuerpo anti-vegfr2 humano para terapia del cancer anti-angiogenica y dirigida. | |
| WO2021150936A1 (en) | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer | |
| WO2020081579A8 (en) | Monoclonal antibodies against human dickkopf3 and uses thereof | |
| Woller et al. | Virus infection, inflammation and prevention of cancer | |
| Cachot et al. | 545 Tumor-specific cytolytic CD4 T cells mediate protective immunity against human cancer | |
| Jacobsen et al. | 544 Multiomic characterization of T-cell populations at the single-cell level utilizing sensitive dextramers and BD® AbSeq on the BD RhapsodyTM Single-Cell Analysis system | |
| Hammitzsch et al. | AB0022 comparison of in vitro effects of kinase and epigenetic inhibitors on TH17 responses in inflammatory arthritis | |
| Jin et al. | IMMU-15. A UNIQUE SELF-STIMULATIVE PROPERTY OF CD70 CAR ADVANCES T CELL FUNCTION AND ANTI-TUMOR RESPONSE IN GLIOBLASTOMA | |
| Vaishnav et al. | Nanobytes-molecular and immuno-oncology |